PARP inhibitors | GenomeWeb

PARP inhibitors

Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' Rubraca studies.

FDA clearance of the first NGS companion diagnostic paves the way for other comprehensive genomic profiling tests, but Foundation will have to educate docs on the benefits of its test.

The test is approved to identify patients who harbor BRCA mutations and are therefore more likely to respond to Clovis Oncology's ovarian cancer drug Rubraca.

Myriad filed the first PMA module with the FDA, though based on the agency's feedback it's unclear whether it will view myChoice HRD as a companion or complementary test.

According to Myriad, the NOVA study shows that myChoice HRD can double the number of ovarian cancer patients who will respond to niraparib compared to other tests.

Lynparza is just the start of an expansive portfolio of treatments targeting DNA damage response that AstraZeneca said it will advance with companion tests.

The BRCA Tumor MASTR Plus Dx assay identifies somatic mutations in the BRCA1 and BRCA2 genes in FFPE tumor tissue from ovarian cancer patients.

The company will use Myriad's myChoice HRD companion diagnostic to identify lung cancer patients who would be likely to respond to the drug.

Researchers believe that blocking c-Met and PARP1 may help patients with TNBC, and possibly other cancers, overcome resistance to PARP inhibitors.

Along with breast, ovarian, and pancreatic cancers, the "signature 3" mutation pattern was detected in around 10 percent of sequenced gastric tumors.

Pages

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.